ZELDA THERAPEUTICS LTD. ORDINARY SHARES (OTCMKTS:ZLDAF) Sellers Rose By 1262.5% Their Shorts

ZELDA THERAPEUTICS LTD. ORDINARY SHARES (OTCMKTS:ZLDAF) recorded an increase of 1262.5% in shorted shares. It was announced in December by FINRA the 65,400 shorted shares on ZLDAF. That’s 1262.5% up from 4,800 shares. 0 days will cost ZLDAF with 276,800 average volume to recover its previous position.

$0.032 was the last price.Since December 8, 2017 it’s 0.00% down thus . ZLDAF underperformed by 15.62% the S&P 500.

Zelda Therapeutics Limited, a bio-pharmaceutical company, focuses on developing a range of cannabinoid formulations for the treatment of various medical conditions in Australia.The firm is valued at $27.27 million. The firm is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer.Currently it has negative earnings. It has strategic alliances with Knop Laboratories and CannPal Pty Ltd; and partnerships with AusCann Limited and Aunt Zelda??s Inc, as well as the Complutens?? University, the Curtin University, and the Telethon Kids Institute.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.